AMDL Gets Deal, Expects Revenue for 1st Time

AMDL Inc., a biomedical company, said Monday it expects to generate revenue next year for the first time.

A deal to distribute the company’s lung cancer test in Indonesia, plus similar agreements being negotiated in other countries, also may enable the company to break even next year, said That T. Ngo, the company’s president and chief executive.

AMDL said a Fullerton company, Stocs Inc., has agreed to distribute AMDL’s test in Indonesia. The test is being marketed by a joint venture of AMDL and a Canadian company, Briana Bio-Tech Inc.

Ngo said his company is scheduled to receive a minimum of $3.5 million over the next four years from the Indonesian distribution agreement. AMDL expects to receive the first $350,000 next year, which will provide the company’s initial revenue. AMDL has lost more than $6 million in the last six years, Ngo said.